Title:MIR17HG: A Cancerogenic Long-Noncoding RNA in Different Cancers
Volume: 28
Issue: 15
Author(s): Fangshun Tan, Jinlan Chen, Zhuoying Du, Fangnan Zhao, Yuling Liu, Qi Zhang and Chengfu Yuan*
Affiliation:
- Third-grade Pharmacological Laboratory on Traditional Chinese Medicine, State Administration of Traditional Chinese Medicine,
China Three Gorges University, Yichang, China
- Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China
Three Gorges University, Yichang, China
- Medical College, China Three Gorges University, Yichang 443002, China
Keywords:
Long non-coding RNA, MIR17HG, biomarker, therapeutic molecular target, diagnosis, prognosis, cancer, molecular mechanism.
Abstract: LncRNA MIR17HG, located at chromosome 13q31, plays an inevitable role in promoting tumor
progressions, such as tumorigenesis, proliferation, and metastasis. Besides, lncRNA MIR17HG is rare due to its
open reading frame (ORF), which can be translated to produce protein. By systematically retrieval, we summarized
that MIR17HG is an emerging lncRNA that exhibits carcinogenically in osteosarcoma (OS), glioma, cervical
squamous cell carcinoma (CSCC), colorectal cancer (CRC), gastric cancer (GC), atypical teratoid
rhabdoid tumors (ATRT). Furthermore, a high expression level of MIR17HG protein is also linked with meningioma.
Additionally, MIR17HG polymorphisms in glioma, CRC, liver cancer (LC), breast cancer (BC), head
and neck squamous cell carcinoma (HNSCC), and multiple myeloma (MM) also have a large influence on cancer
susceptibility, prognosis, and so on. Collectively, long non-coding RNA MIR17HG’s tumor-stimulative role
could be a promising therapeutic target. Besides, by investigating patients’ MIR17HG single-nucleotide polymorphisms
(SNPs), clinicians could also personalize the productive interventions in gene therapy or predict the
diagnosis/prognosis precisely.
